Anuh Pharma Limited has informed the Exchange regarding 'Adoption of Memorandum of Association (MOA) and Articles of Association (AOA) as per Companies Act, 2013.'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma Limited reported FY2025-26 results with revenue from operations growing 16.6% YoY to Rs. 77,165.74 Lakhs. However, profit after tax declined 13.3% to Rs. 4,104.61 Lakhs, while EBITDA margin compressed from 10.64% to 8.56%. Operating cash flow turned negative at Rs. -301.16 Lakhs (vs +Rs. 3,712.47 Lakhs in prior year). Inventories nearly doubled to Rs. 14,775.50 Lakhs. The Board recommended a dividend of Rs. 1.50 per share (30% payout). Nine promoter group members (holding 0.95% shares) sought reclassification to public category. The company also approved new MOA/AOA, appointed new internal auditors (RMJ & Associates LLP), and a new GM-Quality.
Despite revenue growth, the sharp decline in profitability, margin compression, and negative operating cash flow signal operational stress. Shareholders may face pressure on returns despite the dividend recommendation.